Linghui Pan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Linghui Pan has a total of 241 co-authors. Here are the top co-authors by number of shared publications:
Fei Lin
Department of Anesthesiology, Guangxi Medical University Cancer Hospital, Nanning, PR China
19 shared publicationsRen Jing
Guangxi Clinical Research Center for Anesthesiology, Guangxi Medical University Cancer Hospital
16 shared publicationsHuijun Dai
Guangxi Clinical Research Center for Anesthesiology, Nanning 530021, PR China; Guangxi Engineering Research Center for Tissue & Organ Injury and Repair Medicine, Nanning 530021, PR China; Guangxi Health Commission Key Laboratory of Basic Science and Prevention of Perioperative Organ Disfunction, Nanning 530021, PR China; Department of Anesthesiology, Guangxi Medical University Cancer Hospital, Nanning 530021, PR China
14 shared publicationsMaoyao Ling
Department of Anesthesiology, Guangxi Medical University Cancer Hospital, Liang Yu Rd No.50, Nanning, 530021, PR China
11 shared publicationsSheng He
The First Affiliated Hospital, Department of Anesthesiology, Hengyang Medical School, University of South China
11 shared publicationsXiaoting Liao
Department of Anesthesiology, Guangxi Medical University Cancer Hospital, Liang Yu Rd No.50, Nanning, 530021, PR China
11 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1928236
Neurological adverse events associated with immune checkpoint inhibitors: a pharmacovigilance study based on the FAERS and JADER databases
Background: Neurological adverse events (NAEs) have been reported during immune checkpoint inhibitor (ICI) therapy, but their reporting spectrum and onset patterns across drugs and pharmacovigilance databases remain incompletely characterized. Methods: We conducted a pharmacovigilance study of seven ICIs using the FDA Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report (JADER) database. Primary drug–preferred term (PT) signals were evaluated using whole-database disproportionality analyses. An exploratory FAERS analysis compared PD-L1 with PD-1 inhibitors within study-defined tumor-indicator strata. Factors associated with NAE reporting were assessed in FAERS by univariate and multivariable logistic regression, and time-to-onset (TTO) was summarized using descriptive statistics and Weibull analyses. JADER cemiplimab data were summarized descriptively only because of sparse reporting. Results: The analysis included 3,915 NAE reports from FAERS and 2,929 from JADER. The heatmaps displayed 111 positive drug–PT pairs across 31 PTs in FAERS and 49 across 16 PTs in JADER. Myasthenia gravis showed a disproportionality signal for all seven ICIs in non-Japanese FAERS reports and for all six ICIs included in the JADER signal analysis; encephalitis-related terms and immune-mediated myositis also recurred, although drug-specific patterns varied. In FAERS, complete-case regression included 111,879 ICI-related reports with 2,887 NAEs. Age ≥65 years and ICI combination therapy were associated with higher adjusted odds of NAE reporting, whereas PD-L1 and CTLA-4 monotherapy were associated with lower adjusted reporting odds relative to PD-1 monotherapy. The stratified comparison showed lower myasthenia gravis reporting odds for PD-L1 than PD-1 in both strata; encephalitis confidence intervals included 1. Drug-level median TTOs ranged from 16 to 43 days in FAERS and from 16 to 32 days in JADER, with heterogeneous Weibull patterns across drugs and databases. Conclusion: ICI-associated neurological reports showed recurring neuromuscular and central nervous system signals, partial qualitative concordance between non-Japanese FAERS reports and JADER, and heterogeneous onset patterns across drugs. The observed reporting associations do not establish comparative clinical safety. Overall, these findings are descriptive and hypothesis-generating and warrant confirmation in studies with exposure denominators, clinically adjudicated diagnoses, and longitudinal follow-up.
- 5 November 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1928236
Open AccessNeurological adverse events associated with immune checkpoint inhibitors: a pharmacovigilance study based on the FAERS and JADER databases
Background: Neurological adverse events (NAEs) have been reported during immune checkpoint inhibitor (ICI) therapy, but their reporting spectrum and onset patterns across drugs and pharmacovigilance databases remain incompletely characterized. Methods: We conducted a pharmacovigilance study of seven ICIs using the FDA Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report (JADER) database. Primary drug–preferred term (PT) signals were evaluated using whole-database disproportionality analyses. An exploratory FAERS analysis compared PD-L1 with PD-1 inhibitors within study-defined tumor-indicator strata. Factors associated with NAE reporting were assessed in FAERS by univariate and multivariable logistic regression, and time-to-onset (TTO) was summarized using descriptive statistics and Weibull analyses. JADER cemiplimab data were summarized descriptively only because of sparse reporting. Results: The analysis included 3,915 NAE reports from FAERS and 2,929 from JADER. The heatmaps displayed 111 positive drug–PT pairs across 31 PTs in FAERS and 49 across 16 PTs in JADER. Myasthenia gravis showed a disproportionality signal for all seven ICIs in non-Japanese FAERS reports and for all six ICIs included in the JADER signal analysis; encephalitis-related terms and immune-mediated myositis also recurred, although drug-specific patterns varied. In FAERS, complete-case regression included 111,879 ICI-related reports with 2,887 NAEs. Age ≥65 years and ICI combination therapy were associated with higher adjusted odds of NAE reporting, whereas PD-L1 and CTLA-4 monotherapy were associated with lower adjusted reporting odds relative to PD-1 monotherapy. The stratified comparison showed lower myasthenia gravis reporting odds for PD-L1 than PD-1 in both strata; encephalitis confidence intervals included 1. Drug-level median TTOs ranged from 16 to 43 days in FAERS and from 16 to 32 days in JADER, with heterogeneous Weibull patterns across drugs and databases. Conclusion: ICI-associated neurological reports showed recurring neuromuscular and central nervous system signals, partial qualitative concordance between non-Japanese FAERS reports and JADER, and heterogeneous onset patterns across drugs. The observed reporting associations do not establish comparative clinical safety. Overall, these findings are descriptive and hypothesis-generating and warrant confirmation in studies with exposure denominators, clinically adjudicated diagnoses, and longitudinal follow-up.
- Open Access
- 6 August 2026
- Published by Springer Nature in Holistic Integrative Oncology
- Vol. 5 (1) , 63
Perioperative stress–inflammation–immunosuppression axis and tumor progression: mechanistic integration and anesthetic management strategies
Perioperative stress is an unavoidable part of surgery and may be particularly relevant in patients with cancer. Surgical trauma activates two major stress pathways, the hypothalamic–pituitary–adrenal (HPA) axis and the sympathetic nervous system (SNS), leading to surges in stress hormones, inflammatory mediators, and a temporary reduction in anti-tumor immune function. This sequence can be described as a stress–inflammation–immunosuppression axis. Experimental studies suggest that excessive activation of this axis may support postoperative survival and spread of residual tumor cells, yet clinical outcome data remain inconsistent and often depend on cancer type, stage, and the overall perioperative care bundle. This review integrates mechanistic evidence on how perioperative stress and inflammation reshape immune surveillance, including effects on natural killer (NK) cells, cytotoxic T lymphocytes, myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), and neutrophil extracellular traps (NETs). We also summarize how commonly used anesthetic drugs and techniques may modify stress signaling, inflammation, and immune function, and we critically appraise the current clinical evidence linking anesthetic management to biomarkers and oncologic outcomes. Finally, we propose an executable framework for individualized anesthetic planning that focuses on reducing stress peaks, limiting avoidable physiologic instability, supporting early recovery, and shortening the postoperative window of immunosuppression within enhanced recovery pathways.
- 6 August 2026
- Published by Springer Nature in Holistic Integrative Oncology
- Vol. 5 (1) , 63
Open AccessPerioperative stress–inflammation–immunosuppression axis and tumor progression: mechanistic integration and anesthetic management strategies
Perioperative stress is an unavoidable part of surgery and may be particularly relevant in patients with cancer. Surgical trauma activates two major stress pathways, the hypothalamic–pituitary–adrenal (HPA) axis and the sympathetic nervous system (SNS), leading to surges in stress hormones, inflammatory mediators, and a temporary reduction in anti-tumor immune function. This sequence can be described as a stress–inflammation–immunosuppression axis. Experimental studies suggest that excessive activation of this axis may support postoperative survival and spread of residual tumor cells, yet clinical outcome data remain inconsistent and often depend on cancer type, stage, and the overall perioperative care bundle. This review integrates mechanistic evidence on how perioperative stress and inflammation reshape immune surveillance, including effects on natural killer (NK) cells, cytotoxic T lymphocytes, myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), and neutrophil extracellular traps (NETs). We also summarize how commonly used anesthetic drugs and techniques may modify stress signaling, inflammation, and immune function, and we critically appraise the current clinical evidence linking anesthetic management to biomarkers and oncologic outcomes. Finally, we propose an executable framework for individualized anesthetic planning that focuses on reducing stress peaks, limiting avoidable physiologic instability, supporting early recovery, and shortening the postoperative window of immunosuppression within enhanced recovery pathways.
- Open Access
- 1 July 2026
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (7) , 774
Evolutionary patterns and research frontiers in ventilator-induced lung injury: a bibliometric analysis (2000–2024)
Background: Ventilator-induced lung injury (VILI) is a major complication of mechanical ventilation and contributes substantially to morbidity and mortality in critically ill patients. Despite extensive investigations into the pathophysiological mechanisms and preventive strategies of VILI, the global research landscape, collaborative networks, and emerging trends in this field have not been comprehensively characterized. This study aimed to systematically evaluate the development, research hotspots, and future directions of VILI research through bibliometric analysis. Methods: Publications related to VILI published between 2000 and 2024 were retrieved from the Web of Science Core Collection (WoSCC). Bibliometric indicators, including annual publication output, citations, countries, institutions, authors, journals, and keywords, were analyzed. Visualization and network analyses were conducted using Bibliometrix (R package), VOSviewer, and CiteSpace to identify research collaborations, influential contributors, knowledge structures, and emerging research themes. Results: A total of 4,055 publications were included in the analysis. The annual number of publications (NP) and citations demonstrated a sustained upward trend, reflecting growing scientific interest in VILI. The United States was the leading contributor in terms of publication output, citations, and international collaborations. Harvard University and other major academic institutions played central roles in advancing the field. Highly cited studies primarily focused on lung-protective ventilation strategies, mechanical stress-induced inflammatory responses, and acute respiratory distress syndrome (ARDS). Keyword co-occurrence, burst detection, and thematic analyses revealed that inflammation, oxidative stress, NLRP3 inflammasome activation, epithelial and endothelial barrier dysfunction, mechanotransduction, and precision ventilation strategies have emerged as major research hotspots. Recent studies increasingly focus on molecular mechanisms and translational interventions aimed at reducing ventilator-associated lung damage. Conclusions: Research on VILI has expanded substantially over the past two decades, with increasing global collaboration and diversification of research themes. Current hotspots have shifted from clinical ventilation strategies toward mechanistic investigations involving inflammatory signaling pathways and cellular injury processes. These findings provide a comprehensive overview of the intellectual structure and developmental trajectory of VILI research and may help guide future basic, translational, and clinical investigations in this field.
- 1 July 2026
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 18 (7) , 774
Open AccessEvolutionary patterns and research frontiers in ventilator-induced lung injury: a bibliometric analysis (2000–2024)
Background: Ventilator-induced lung injury (VILI) is a major complication of mechanical ventilation and contributes substantially to morbidity and mortality in critically ill patients. Despite extensive investigations into the pathophysiological mechanisms and preventive strategies of VILI, the global research landscape, collaborative networks, and emerging trends in this field have not been comprehensively characterized. This study aimed to systematically evaluate the development, research hotspots, and future directions of VILI research through bibliometric analysis. Methods: Publications related to VILI published between 2000 and 2024 were retrieved from the Web of Science Core Collection (WoSCC). Bibliometric indicators, including annual publication output, citations, countries, institutions, authors, journals, and keywords, were analyzed. Visualization and network analyses were conducted using Bibliometrix (R package), VOSviewer, and CiteSpace to identify research collaborations, influential contributors, knowledge structures, and emerging research themes. Results: A total of 4,055 publications were included in the analysis. The annual number of publications (NP) and citations demonstrated a sustained upward trend, reflecting growing scientific interest in VILI. The United States was the leading contributor in terms of publication output, citations, and international collaborations. Harvard University and other major academic institutions played central roles in advancing the field. Highly cited studies primarily focused on lung-protective ventilation strategies, mechanical stress-induced inflammatory responses, and acute respiratory distress syndrome (ARDS). Keyword co-occurrence, burst detection, and thematic analyses revealed that inflammation, oxidative stress, NLRP3 inflammasome activation, epithelial and endothelial barrier dysfunction, mechanotransduction, and precision ventilation strategies have emerged as major research hotspots. Recent studies increasingly focus on molecular mechanisms and translational interventions aimed at reducing ventilator-associated lung damage. Conclusions: Research on VILI has expanded substantially over the past two decades, with increasing global collaboration and diversification of research themes. Current hotspots have shifted from clinical ventilation strategies toward mechanistic investigations involving inflammatory signaling pathways and cellular injury processes. These findings provide a comprehensive overview of the intellectual structure and developmental trajectory of VILI research and may help guide future basic, translational, and clinical investigations in this field.
- Open Access
- 24 June 2026
- Published by Springer Nature in Respiratory Research
- Vol. 27 (1)
Mechanical ventilation activates PERK/eIF2α and NOD1 pathways that contribute to NF-κB–driven inflammation in VILI
Ventilator-induced lung injury (VILI) is characterized by acute lung damage and NF-κB-driven cytokine production during mechanical ventilation. However, the upstream signals that initiate and exacerbate NF-κB-driven inflammation remain poorly understood. Although endoplasmic reticulum (ER) stress is implicated in VILI, how ER stress pathways interact with innate immune sensors to promote inflammation is incompletely defined. Here, we investigate the roles of NOD1 and the ER stress-responsive PERK/eIF2α pathway in a VILI mice model. C57BL/6 mice were subjected to high-tidal volume (HTV) ventilation for 4 h to establish an in vivo model of VILI. To investigate the role of NOD1 in VILI, Nod1-knockout (Nod1-KO) mice were generated. To further determine the involvement of the PERK pathway, wild-type and Nod1-KO mice were treated with PERK inhibitor GSK2606414 prior to HTV ventilation. Lung injury was evaluated using H&E staining, wet/dry ratio, and analysis of bronchoalveolar lavage fluid (BALF) for total protein concentration and inflammatory cell counts. Inflammatory cytokine levels were quantified by ELISA. Relative proteins expression was analyzed by immunoblotting and immunofluorescence. HTV ventilation induced lung histopathological damage, alveolar-capillary barrier dysfunction, and increased levels of IL-1β, IL-6, and TNF-α, along with upregulation of NOD1 and the ER stress marker GRP78. Genetic deletion of Nod1 attenuated lung injury and inflammatory cytokine release, associated with reduced GRP78 abundance and decreased NF-κB activation. In parallel, HTV increased phosphorylation of PERK and eIF2α, and pharmacological inhibition of PERK with GSK2606414 ameliorated lung injury and inflammation while suppressing NF-κB activation, without altering NOD1 protein abundance. Notably, combining NOD1 deficiency with PERK inhibition produced more pronounced protection against HTV-induced lung injury than either intervention alone, whereas the reduction of NF-κB readouts did not further deepen under the combined condition. HTV-induced inflammatory lung injury is associated with activation of both NOD1 and PERK/eIF2α signaling. Mechanistically, these pathways contribute to NF-κB-associated inflammatory responses and lung injury in VILI. Notably, the greater protection observed under combined NOD1 deficiency and PERK inhibition, despite a plateau in NF-κB readouts, suggests that additional injury mechanisms beyond NF-κB may also be involved.
- 24 June 2026
- Published by Springer Nature in Respiratory Research
- Vol. 27 (1)
Open AccessMechanical ventilation activates PERK/eIF2α and NOD1 pathways that contribute to NF-κB–driven inflammation in VILI
Ventilator-induced lung injury (VILI) is characterized by acute lung damage and NF-κB-driven cytokine production during mechanical ventilation. However, the upstream signals that initiate and exacerbate NF-κB-driven inflammation remain poorly understood. Although endoplasmic reticulum (ER) stress is implicated in VILI, how ER stress pathways interact with innate immune sensors to promote inflammation is incompletely defined. Here, we investigate the roles of NOD1 and the ER stress-responsive PERK/eIF2α pathway in a VILI mice model. C57BL/6 mice were subjected to high-tidal volume (HTV) ventilation for 4 h to establish an in vivo model of VILI. To investigate the role of NOD1 in VILI, Nod1-knockout (Nod1-KO) mice were generated. To further determine the involvement of the PERK pathway, wild-type and Nod1-KO mice were treated with PERK inhibitor GSK2606414 prior to HTV ventilation. Lung injury was evaluated using H&E staining, wet/dry ratio, and analysis of bronchoalveolar lavage fluid (BALF) for total protein concentration and inflammatory cell counts. Inflammatory cytokine levels were quantified by ELISA. Relative proteins expression was analyzed by immunoblotting and immunofluorescence. HTV ventilation induced lung histopathological damage, alveolar-capillary barrier dysfunction, and increased levels of IL-1β, IL-6, and TNF-α, along with upregulation of NOD1 and the ER stress marker GRP78. Genetic deletion of Nod1 attenuated lung injury and inflammatory cytokine release, associated with reduced GRP78 abundance and decreased NF-κB activation. In parallel, HTV increased phosphorylation of PERK and eIF2α, and pharmacological inhibition of PERK with GSK2606414 ameliorated lung injury and inflammation while suppressing NF-κB activation, without altering NOD1 protein abundance. Notably, combining NOD1 deficiency with PERK inhibition produced more pronounced protection against HTV-induced lung injury than either intervention alone, whereas the reduction of NF-κB readouts did not further deepen under the combined condition. HTV-induced inflammatory lung injury is associated with activation of both NOD1 and PERK/eIF2α signaling. Mechanistically, these pathways contribute to NF-κB-associated inflammatory responses and lung injury in VILI. Notably, the greater protection observed under combined NOD1 deficiency and PERK inhibition, despite a plateau in NF-κB readouts, suggests that additional injury mechanisms beyond NF-κB may also be involved.
- Open Access
- 28 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1886583
Correction: Spatiotemporal regulation of ventilator lung injury resolution by TGF-β1+ regulatory b cells via macrophage vesicle-nanotherapeutics
Error in Figure 2A There was a mistake in Figure 2A as published. The images for the NTV1d and NTV10d groups have been replaced with correct images obtained from the same experimental conditions. The publisher apologizes for this mistake.In the published article, there was a mistake in Figure 2A. The images for the NTV1d and NTV10d groups were misused. Upon reexamination of the original experimental data, we found that incorrect representative images had been selected during figure assembly. These have now been replaced with the correct images obtained from the same experimental conditions. The corrected Figure 2A appears below.
- 28 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1886583
Open AccessCorrection: Spatiotemporal regulation of ventilator lung injury resolution by TGF-β1+ regulatory b cells via macrophage vesicle-nanotherapeutics
Error in Figure 2A There was a mistake in Figure 2A as published. The images for the NTV1d and NTV10d groups have been replaced with correct images obtained from the same experimental conditions. The publisher apologizes for this mistake.In the published article, there was a mistake in Figure 2A. The images for the NTV1d and NTV10d groups were misused. Upon reexamination of the original experimental data, we found that incorrect representative images had been selected during figure assembly. These have now been replaced with the correct images obtained from the same experimental conditions. The corrected Figure 2A appears below.
- Open Access
- 11 May 2026
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 26 (1)
HSP90AA1 inhibits the Jun/Fos pathway to rescue hepatocytes from cuproptosis during ischemia-reperfusion injury
Hepatic ischemia-reperfusion injury (HIRI), a frequent complication in procedures like hepatic lobectomy and organ transplantation, remains a significant clinical challenge despite advances in protective strategies. Cuproptosis, a copper-dependent form of cell death, has recently been linked to various inflammatory diseases, including HIRI. In this study, bioinformatic analyses were employed to identify differentially expressed core genes, and animal and cellular models of HIRI were established using C57BL/6 mice and AML12 cells to investigate the roles of HSP90AA1 and c-Jun/c-Fos-mediated cuproptosis in HIRI. Techniques including RT-qPCR, Western blotting, immunohistochemistry, immunofluorescence, and electron microscopy were used to assess cuproptosis, inflammation, and mitochondrial damage. Bioinformatic results indicated that HSP90AA1 and the Jun/Fos pathway are likely key targets in HIRI. Notably, increased cuproptosis and elevated HSP90AA1 expression in hepatocytes were observed both in vivo and in vitro following HIRI. Furthermore, HSP90AA1 overexpression significantly attenuated I/R-induced liver injury and cuproptosis by suppressing the Jun/Fos pathway. These findings reveal, for the first time, that HSP90AA1 can mitigate cuproptosis induced by HIRI via regulation of the Jun/Fos pathway, suggesting a potential novel therapeutic approach for HIRI.
- 11 May 2026
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 26 (1)
Open AccessHSP90AA1 inhibits the Jun/Fos pathway to rescue hepatocytes from cuproptosis during ischemia-reperfusion injury
Hepatic ischemia-reperfusion injury (HIRI), a frequent complication in procedures like hepatic lobectomy and organ transplantation, remains a significant clinical challenge despite advances in protective strategies. Cuproptosis, a copper-dependent form of cell death, has recently been linked to various inflammatory diseases, including HIRI. In this study, bioinformatic analyses were employed to identify differentially expressed core genes, and animal and cellular models of HIRI were established using C57BL/6 mice and AML12 cells to investigate the roles of HSP90AA1 and c-Jun/c-Fos-mediated cuproptosis in HIRI. Techniques including RT-qPCR, Western blotting, immunohistochemistry, immunofluorescence, and electron microscopy were used to assess cuproptosis, inflammation, and mitochondrial damage. Bioinformatic results indicated that HSP90AA1 and the Jun/Fos pathway are likely key targets in HIRI. Notably, increased cuproptosis and elevated HSP90AA1 expression in hepatocytes were observed both in vivo and in vitro following HIRI. Furthermore, HSP90AA1 overexpression significantly attenuated I/R-induced liver injury and cuproptosis by suppressing the Jun/Fos pathway. These findings reveal, for the first time, that HSP90AA1 can mitigate cuproptosis induced by HIRI via regulation of the Jun/Fos pathway, suggesting a potential novel therapeutic approach for HIRI.
- Open Access
- 17 February 2026
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 31, e950289
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinformatics and Experimental Approach
BACKGROUND Acute lung injury (ALI) after liver transplantation (LT) is a critical complication negatively affecting transplant outcomes and patient survival. However, effective biomarkers for early diagnosis remain unidentified. This study aimed to identify hub biomarkers and signaling pathways involved in post-LT ALI through integrated bioinformatics and machine-learning analyses and to validate their diagnostic potential. MATERIAL AND METHODS Differential gene expression analysis identified 27 differentially expressed genes (DEGs). Functional enrichment analyses revealed significant involvement in cytokine-mediated signaling, particularly within the NF-kB and TNF pathways. Single-sample gene set enrichment analysis (ssGSEA) evaluated immune infiltration. Machine-learning algorithms identified crucial biomarkers for ALI prediction. Transcription factor-hub gene and competitive endogenous RNA (ceRNA) networks were constructed. Single-cell RNA sequencing (scRNA-seq) and enzyme-linked immunosorbent assay (ELISA) analyses validated biomarker expression patterns in relation to ALI. RESULTS Hub biomarkers identified included CXCL3, CD48, and IRAK3. ssGSEA revealed prominent macrophage and neutrophil infiltration associated with ALI. Machine-learning models confirmed CXCL3, CD48, and IRAK3 as reliable predictive biomarkers, which were incorporated into a robust diagnostic nomogram. scRNA-seq analysis showed cell-type-specific expression patterns for CXCL3, CD48, and IRAK3, with heterogeneous associations across datasets. ELISA validated significantly altered protein levels of CXCL3, CD48, and IRAK3 in post-transplant ALI cases compared with controls. CONCLUSIONS CXCL3, CD48, and IRAK3 are novel and promising diagnostic biomarkers for predicting post-LT ALI. These findings provide foundational insights that could support improved diagnosis, prevention strategies, and targeted therapeutic interventions, ultimately enhancing patient outcomes after liver transplantation.
- 17 February 2026
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 31, e950289
Open AccessIdentification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinformatics and Experimental Approach
BACKGROUND Acute lung injury (ALI) after liver transplantation (LT) is a critical complication negatively affecting transplant outcomes and patient survival. However, effective biomarkers for early diagnosis remain unidentified. This study aimed to identify hub biomarkers and signaling pathways involved in post-LT ALI through integrated bioinformatics and machine-learning analyses and to validate their diagnostic potential. MATERIAL AND METHODS Differential gene expression analysis identified 27 differentially expressed genes (DEGs). Functional enrichment analyses revealed significant involvement in cytokine-mediated signaling, particularly within the NF-kB and TNF pathways. Single-sample gene set enrichment analysis (ssGSEA) evaluated immune infiltration. Machine-learning algorithms identified crucial biomarkers for ALI prediction. Transcription factor-hub gene and competitive endogenous RNA (ceRNA) networks were constructed. Single-cell RNA sequencing (scRNA-seq) and enzyme-linked immunosorbent assay (ELISA) analyses validated biomarker expression patterns in relation to ALI. RESULTS Hub biomarkers identified included CXCL3, CD48, and IRAK3. ssGSEA revealed prominent macrophage and neutrophil infiltration associated with ALI. Machine-learning models confirmed CXCL3, CD48, and IRAK3 as reliable predictive biomarkers, which were incorporated into a robust diagnostic nomogram. scRNA-seq analysis showed cell-type-specific expression patterns for CXCL3, CD48, and IRAK3, with heterogeneous associations across datasets. ELISA validated significantly altered protein levels of CXCL3, CD48, and IRAK3 in post-transplant ALI cases compared with controls. CONCLUSIONS CXCL3, CD48, and IRAK3 are novel and promising diagnostic biomarkers for predicting post-LT ALI. These findings provide foundational insights that could support improved diagnosis, prevention strategies, and targeted therapeutic interventions, ultimately enhancing patient outcomes after liver transplantation.
- Open Access
- 20 January 2026
- Published by Wiley in Cell Proliferation
- Vol. 59 (7) , e70164
Agrimoniin Alleviates Ferroptosis in Cold‐Stored DCD Liver Grafts Through Activation of the Nrf‐2 Pathway
Liver grafts from donation‐after‐cardiac‐death (DCD) are vulnerable to ischemia–reperfusion injury, which compromises graft function after transplantation. Agrimoniin has been shown to possess antioxidant and anti‐inflammatory properties, making it a potential therapeutic agent for organ preservation. This study investigated whether supplementing agrimoniin to the University of Wisconsin (UW) cold storage solution protected liver grafts from DCD rats or cold preserved human liver cell lines (QSG‐7701 and HepG2). Agrimoniin supplementation significantly reduced oxidative damage, alleviated ferroptosis, and mitigated liver injury by activating the Nrf‐2 pathway, both in vivo and in vitro. These findings suggest that ferroptosis is a mediator in DCD liver injury, and agrimoniin, through its activation of the Nrf‐2 pathway, may be an effective therapeutic agent for enhancing liver graft preservation and improving outcomes in DCD liver transplantation.
- 20 January 2026
- Published by Wiley in Cell Proliferation
- Vol. 59 (7) , e70164
Open AccessAgrimoniin Alleviates Ferroptosis in Cold‐Stored DCD Liver Grafts Through Activation of the Nrf‐2 Pathway
Liver grafts from donation‐after‐cardiac‐death (DCD) are vulnerable to ischemia–reperfusion injury, which compromises graft function after transplantation. Agrimoniin has been shown to possess antioxidant and anti‐inflammatory properties, making it a potential therapeutic agent for organ preservation. This study investigated whether supplementing agrimoniin to the University of Wisconsin (UW) cold storage solution protected liver grafts from DCD rats or cold preserved human liver cell lines (QSG‐7701 and HepG2). Agrimoniin supplementation significantly reduced oxidative damage, alleviated ferroptosis, and mitigated liver injury by activating the Nrf‐2 pathway, both in vivo and in vitro. These findings suggest that ferroptosis is a mediator in DCD liver injury, and agrimoniin, through its activation of the Nrf‐2 pathway, may be an effective therapeutic agent for enhancing liver graft preservation and improving outcomes in DCD liver transplantation.
- Open Access
- 13 January 2026
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 309, 119710
Article title: Associations between paraben exposure and breast cancer risk: An integrative epidemiologic, network toxicology, multi-omics and experimental analysis
- 13 January 2026
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 309, 119710
Open AccessArticle title: Associations between paraben exposure and breast cancer risk: An integrative epidemiologic, network toxicology, multi-omics and experimental analysis
- Open Access
- 26 September 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-20
Integrated multi-omics analysis reveals PTM networks as key regulators of colorectal cancer progression and immune evasion
Background Colorectal cancer (CRC) is a leading cause of cancer mortality, with treatment resistance often driven by molecular heterogeneity and an immunosuppressive tumor microenvironment (TME). Post-translational modifications (PTMs) regulate key oncogenic processes, but their comprehensive role in CRC progression and immune evasion remains unexplored. Methods We integrated multi-omics data from bulk RNA-seq (GEO/TCGA, n = 1,783), single-cell transcriptomics (41,143 cells), and Mendelian randomization. Differential expression, GSVA, and machine learning (LASSO/SVM/Random Forest) were used to identify PTM-associated signatures. Functional validation included spatial transcriptomics, and immune profiling. Results Multi-omics analysis identified dysregulation in 80% of PTM pathways in CRC, with ubiquitination sustaining Wnt/β-catenin signaling and GALNT6-mediated glycosylation driving immune evasion through PD-L1 stabilization and CD8 + T cell exclusion. Single-cell analysis revealed GALNT6-specific enrichment in immune-excluded goblet cells (p < 0.05). Machine learning derived a 5-gene PTM Activity Signature (CCNB1IP1, GALNT6, NEDD4L, PSMD14, UBE2C) that distinguish between patients with diseases and those without (AUC = 1.00). GALNT6 was validated as a causal risk factor (OR = 1.10, 95%CI:1.01–1.18), with its inhibition synergizing with anti-PD-1 to enhance CD8 + T cell infiltration (p < 0.01). Conclusion This study establishes PTM networks as central regulators of CRC progression and immune resistance. The PTM-AS framework enables precision subtyping, while GALNT6 emerges as a novel therapeutic target for overcoming immunotherapy resistance.
- 26 September 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-20
Open AccessIntegrated multi-omics analysis reveals PTM networks as key regulators of colorectal cancer progression and immune evasion
Background Colorectal cancer (CRC) is a leading cause of cancer mortality, with treatment resistance often driven by molecular heterogeneity and an immunosuppressive tumor microenvironment (TME). Post-translational modifications (PTMs) regulate key oncogenic processes, but their comprehensive role in CRC progression and immune evasion remains unexplored. Methods We integrated multi-omics data from bulk RNA-seq (GEO/TCGA, n = 1,783), single-cell transcriptomics (41,143 cells), and Mendelian randomization. Differential expression, GSVA, and machine learning (LASSO/SVM/Random Forest) were used to identify PTM-associated signatures. Functional validation included spatial transcriptomics, and immune profiling. Results Multi-omics analysis identified dysregulation in 80% of PTM pathways in CRC, with ubiquitination sustaining Wnt/β-catenin signaling and GALNT6-mediated glycosylation driving immune evasion through PD-L1 stabilization and CD8 + T cell exclusion. Single-cell analysis revealed GALNT6-specific enrichment in immune-excluded goblet cells (p < 0.05). Machine learning derived a 5-gene PTM Activity Signature (CCNB1IP1, GALNT6, NEDD4L, PSMD14, UBE2C) that distinguish between patients with diseases and those without (AUC = 1.00). GALNT6 was validated as a causal risk factor (OR = 1.10, 95%CI:1.01–1.18), with its inhibition synergizing with anti-PD-1 to enhance CD8 + T cell infiltration (p < 0.01). Conclusion This study establishes PTM networks as central regulators of CRC progression and immune resistance. The PTM-AS framework enables precision subtyping, while GALNT6 emerges as a novel therapeutic target for overcoming immunotherapy resistance.